In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Amicus Therapeutics stock can continue to show renewed price strength and clear that threshold.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Amicus Therapeutics Stock A Buy?
Amicus Therapeutics stock had a failed breakout and has pulled back since then. While it's not currently an ideal time to add shares, see if this biotech stock is able to establish and enter a buying range in heavy trade.
The biotech company posted 0% EPS growth last quarter, while sales growth came in at 27%. The next quarterly results are expected on or around Feb. 22.
Amicus Therapeutics stocvk earns the No. 88 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences and Immunogen are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
